These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 27311374)

  • 1. Successful treatment of hepatitis C virus infection combining daclatasvir and simeprevir in a heart transplant recipient with decompensated cirrhosis.
    Casanovas T; Roca J; Niubó J
    J Heart Lung Transplant; 2016 Jul; 35(7):949-51. PubMed ID: 27311374
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
    Nair S; Satapathy SK; Gonzalez HC
    Exp Clin Transplant; 2017 Jun; 15(3):314-319. PubMed ID: 26926117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
    Hézode C; Almasio PL; Bourgeois S; Buggisch P; Brown A; Diago M; Horsmans Y; Serfaty L; Szalay F; Gaeta GB; Planas R; Schlag M; Lonjon-Domanec I; Omoruyi E; DeMasi R; Zeuzem S
    Liver Int; 2017 Sep; 37(9):1304-1313. PubMed ID: 28135777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
    Leroy V; Dumortier J; Coilly A; Sebagh M; Fougerou-Leurent C; Radenne S; Botta D; Durand F; Silvain C; Lebray P; Houssel-Debry P; Kamar N; D'Alteroche L; Petrov-Sanchez V; Diallo A; Pageaux GP; Duclos-Vallee JC;
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1993-2001.e1-2. PubMed ID: 26044317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list.
    Bonacci M; Londoño MC; Esforzado N; Forns X; Sotoca JM; Campistol JM
    Transpl Int; 2015 Nov; 28(11):1345-9. PubMed ID: 26073850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation].
    Hachicha M; Botta-Fridlund D
    Nephrol Ther; 2016 Dec; 12(7):536-538. PubMed ID: 27825643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis.
    Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S
    Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
    Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M
    Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
    Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis.
    Vukotic R; Conti F; Fagiuoli S; Morelli MC; Pasulo L; Colpani M; Foschi FG; Berardi S; Pianta P; Mangano M; Donato MF; Malinverno F; Monico S; Tamè M; Mazzella G; Belli LS; Viganò R; Carrai P; Burra P; Russo FP; Lenci I; Toniutto P; Merli M; Loiacono L; Iemmolo R; Degli Antoni AM; Romano A; Picciotto A; Rendina M; Andreone P;
    J Viral Hepat; 2017 Oct; 24(10):858-864. PubMed ID: 28370880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus genotype 4: Genotype 1's little brother.
    Llaneras J; Riveiro-Barciela M; Buti M; Esteban R
    J Viral Hepat; 2017 Jan; 24(1):4-12. PubMed ID: 27905173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
    Childs-Kean LM; Hand EO
    Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
    Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of hepatitis C patients with decompensated liver disease.
    Hsu CS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of donor-derived hepatitis C infection in a lung transplant recipient.
    Theodoropoulos N; Whitson BA; Martin SI; Pouch S; Pope-Harman A
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
    Werner CR; Schwarz JM; Egetemeyr DP; Beck R; Malek NP; Lauer UM; Berg CP
    World J Gastroenterol; 2016 Sep; 22(35):8050-9. PubMed ID: 27672299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival.
    Giard JM; Terrault NA
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):2002-4. PubMed ID: 26192143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.